A Clinical Validation of Safety and Effectiveness of Pain Relief and Joint Mobility Tablet
Bibliographic record
Abstract
Abstract: Introduction: Millions of people worldwide are dealing with joint discomfort and issues with mobility, which are mostly caused by diseases like rheumatoid arthritis and osteoarthritis. These illnesses not only hurt physically but also seriously limit mobility, which diminishes activity levels and impairs quality of life. Materials and Methods: An open-label, single-arm, safety study was conducted on 32 individuals. One tablet of Pain Relief and Joint Mobility twice daily after a meal for 30 days was given. The research objectives were to evaluate changes in compliance, clinical, vital parameter assessment, and tolerability of the investigational product from baseline to the end of the study. Changes in complete blood count (CBC), liver function test(LFT), and renal function test (RFT)parameters on screening and day 30. Results: The analysis of the vital sign parameters revealed a statistically significant decrease in diastolic blood pressure (p=0.0075) and body temperature (p=0.0133) from the screening to day 30 time points. Hematological and biochemical investigations demonstrated no clinically significant changes from baseline to endpoint, indicating the safety of the intervention. After a 30-day treatment regimen, significant reductions were observed across all Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales: a 32.42%, 34.12%, and 34.76% decrease in pain, stiffness, and physical function scores respectively, indicating substantial alleviation of pain, improvement in stiffness, and enhanced physical function. Conclusion: The study indicates that the Pain Relief and Joint Mobility Tablet is found to be safe and effective in managing joint pain and mobility issues, proving beneficial for patients ranging from those newly diagnosed to those with chronic conditions.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.005 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".